856 Routine baseline blood tests predicting pembrolizumab sensitivity in advanced high-grade serous ovarian cancer (AHGSOC) 1st line therapy: substudy from the NEOPEMBROV/GINECO (NCT03275506) randomized trial

Poster and E-Posters(2024)

引用 0|浏览7
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要